



Anti-inflammatory effects of *Cannabis sativa* L. in human keratinocytes



Enrico Sangiovanni¹, Marco Fumagalli¹, Barbara Pacchetti², Stefano Piazza¹, Mario Dell'Agli¹

¹Dept. of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy ²Linnea SA, Riazzino, Switzerland

INTRODUCTION

Dermatitis and psoriasis are inflammatory diseases in which keratinocytes, the most abundant cells in the epidermis, play a key role in the release of numerous proinflammatory factors (e.g. IL-8, MMP9, and VEGF). Chronic inflammation results from dysregulation and abnormal expression of inflammatory mediators or their receptors in keratinocytes. IL-8 is involved in neutrophil recruitment and VEGF regulates the angiogenesis process, while MMP9 contributes to the degradation of extracellular matrix. These pro-inflammatory mediators are regulated by different transcription factors, including NF- κ B. The downregulation of keratinocytes inflammatory markers and the inhibition of their interaction with immune cells may be an effective target in the treatment of inflammatory skin diseases.

Cannabis sativa L. (C. sativa) is an annual herbaceous plant belonging to the family of Cannabaceae. The flowered tops of this plant contain the highest concentration of cannabinoids like delta-9-tetrahydrocannabinol (Δ 9-THC), cannabidiol (CBD) and its carboxylated form (cannabidiolic acid, CBDA).

CBD is the second major cannabinoid occurring in *C. sativa* and its anti-inflammatory activity on skin has been demonstrated in mice; however, no studies on human keratinocytes inflammation have been reported so far.


AIM OF THE WORK


The aim of this work was to evaluate the anti-inflammatory activity of two C. sativa extracts, standardized in CBD and cannabidiolic acid (CBDA) ($\Delta 9$ -THC < 0.1%), in human keratinocytes.

RESULTS

- ❖ Both the extracts were not cytotoxic till the highest concentration tested of 50 μg/mL.
- * Both the extracts inhibited IL-8, MMP9 and VEGF release and NF-κB driven transcription induced by TNFα, with IC₅₀s below 50 μg/mL, while CBD was active only on NF-κB driven transcription (IC₅₀: 2.85 μM), suggesting that other compounds are involved in the biological activity.
- * The extract containing 5% CBD+CBDA (25 $\mu g/mL$) and the corresponding concentration of cannabidiol (4 μM) were tested on the expression of 84 genes related to inflammation. The extract decreased the mRNA levels of several proinflammatory genes and for some of them CBD was responsible, at least in part, for the activity.







MATERIALS AND METHODS

- ❖ The extracts, containing 1% or 5% CBD+CBDA, were prepared by LINNEA SA (Riazzino, Switzerland).
- * HaCaT cells were grown in 24-well plates (6× 10⁵ cells/well) for 48 h; cells were treated with TNF-α at 10 ng/mL and extracts/compound under study. IL-8 release, NF-κBluc and gene expression were evaluated at 6 h, while MMP-9 and VEGF release at 24 h.
- \clubsuit The cytotoxicity of the extracts and CBD was evaluated by MTT test at 6 and 24 h.
- * IL-8, MMP-9 and VEGF release were analysed by ELISA assays, NF-κB driven transcription by a luciferase reporter plasmid, while gene expression by real-time PCR.

CONCLUSIONS

These results suggest that *C. sativa* extracts may counteract the cutaneous inflammatory processes by interfering with NF-κB pathway.

